ADMA INVESTOR ALERT: Contact Kirby McInerney LLP About Nearing Deadline in Securities Class Action Lawsuit On Behalf of ADMA Biologics, Inc. Investors
NEW YORK CITY, NY / ACCESS Newswire / July 24, 2026 / ( ACCESS NEWSWIRE)-The law firm of Kirby McInerney LLP reminds ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA) securities during the period from August 9, 2024 through May 25, 2026, inclusive (the "Class Period").
If you suffered a loss on your ADMA investments, you have until August 10, 2026 to request lead plaintiff appointment. Courts do not consider applications filed after the lead plaintiff deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. Learn more about the lead plaintiff process and eligibility requirements here.
Follow the link below for more information:
[ CONTACT THE FIRM IF YOU SUFFERED A LOSS]
What Is The Lawsuit About?
The lawsuit alleges that: (1) ADMA engaged in an undisclosed related party transaction; (2) ADMA used channel stuffing to create an appearance of revenue; and (3) ADMA lacked adequate internal controls. Specifically, ADMA, a biopharmaceutical company, allegedly shipped unwanted quantities of ASCENIV, an intravenous immune globulin (IVIG) liquid manufactured by ADMA to treat primary humoral immunodeficiency, to distributors to manufacture the appearance of surging demand. High-level employees at one of ADMA's two largest distributors allegedly confirmed that excess inventory was accumulating in the distribution channel.
On March 24, 2026, Culper Research published a short seller report on ADMA alleging "Channel Stuffing, an Undisclosed Related Party Distributor, and -3% Real Growth in 2025 vs. +20% Reported." Among other things, the report stated that "two high-level employees at one of ADMA's two largest distributors," had confirmed independently that "starting in 2025, ADMA induced the distributor to stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations. Distributors take unwanted product without having to pay for it, ADMA books the revenues, and reports growth that was never there."
On this news, the price of ADMA shares declined by $2.26 per share, or approximately 17%, from $13.59 per share on March 23, 2026 to close at $11.33 on March 24, 2026. The price of ADMA shares declined further by $1.70 per share, or approximately 15%, from $11.33 on March 24, 2026 to close at $9.63 on March 25, 2026.
[ CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]
What Should I Do?
If you purchased or otherwise acquired ADMA securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT THE LEAD PLAINTIFF PROCESS]
Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
[email protected]
SOURCE: Kirby McInerney LLP